Abbott Plans To Spin Off $8.5 Billion Nutrition Business By End Of 2027

The maker of Similac and Ensure would become a separate public company, with Abbott keeping about $42 billion in sales.

Share
Abbott Plans To Spin Off $8.5 Billion Nutrition Business By End Of 2027

Abbott intends to separate its Nutrition business, which has approximately $8.5 billion in annual sales, into an independent public company, according to an 8-K filed Wednesday. Abbott shareholders would receive shares of the new company through a distribution the company intends to be tax-free for U.S. federal income tax purposes.

What the filing says

The 8-K attaches a press release dated Wednesday. Abbott expects to finish the separation by the end of 2027. That is subject to regulatory approvals, an effective registration statement on Form 10 and final approval from its board.

The new company would have about 16,000 employees and 14 manufacturing sites. Its brands include Similac, PediaSure, Pedialyte, Glucerna and Ensure. Daniel Salvadori, now executive vice president and group president, Established Pharmaceuticals and Nutritional Products, will become its chief executive.

After the split, Abbott would have sales of approximately $42 billion and about 106,000 employees. It would keep cardiovascular and neuromodulation devices, biowearables, diagnostics and established medicines.

Chairman and CEO Robert B. Ford said the separation "will benefit both companies."

What it changes for holders

Shareholders would end up owning shares in both companies. Abbott expects the combined dividend from the two to equal Abbott's dividend at the time of separation.

The separation will not affect Abbott's 2026 guidance, or the 2027 guidance it plans to give in January. Abbott expects one-time charges before the split, to be quantified later. The Nutrition business stays inside Abbott until then.

Abbott shares closed at $102.45 on Tuesday, down 1.55% on the session, before the announcement. Abbott said it would discuss the plan on its third-quarter earnings call Wednesday at 9 a.m. Eastern.

Abbott's January 2027 guidance is the next dated event, and the one-time separation charges have yet to be quantified.

Sources

More on Abbott Laboratories

All Abbott Laboratories (ABT) coverage →